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Abstract
Background: Seroepidemiology can provide evidence for temporal changes in malaria transmission and is an
important tool to evaluate the effectiveness of control interventions. During the early 2000s, Vanuatu experienced
an acute increase in malaria incidence due to a lapse in funding for vector control. After the distribution of
subsidised insecticide-treated nets (ITNs) resumed in 2003, malaria incidence decreased in the subsequent years.
This study was conducted to find the serological evidence supporting the impact of ITN on exposure to Anopheles
vector bites and parasite prevalence.
Methods: On Ambae Island, blood samples were collected from 231 and 282 individuals in 2003 and 2007,
respectively. Parasite prevalence was determined by microscopy. Antibodies to three Plasmodium falciparum (PfSE,
PfMSP-119, and PfAMA-1) and three Plasmodium vivax (PvSE, PvMSP-119, and PvAMA-1) antigens, as well as the
Anopheles-specific salivary antigen gSG6, were detected by ELISA. Age-specific seroprevalence was analysed using a
reverse catalytic modelling approach to estimate seroconversion rates (SCRs).
Results: Parasite rate decreased significantly (P < 0.001) from 19.0% in 2003 to 3.2% in 2007, with a shift from P.
falciparum predominance to P. falciparum-P. vivax co-dominance. Significant (P < 0.001) decreases were observed in
seroprevalence to all three P. falciparum antigens but only two of three P. vivax antigens (except PvAMA-1; P = 0.
153), consistent with the more pronounced decrease in P. falciparum prevalence. Seroprevalence to gSG6 also
decreased significantly (P < 0.001), suggesting that reduced exposure to vector bites was important to the decrease
in parasite prevalence between 2003 and 2007. Analyses of age-specific seroprevalence showed a three-fold
decrease in P. falciparum transmission, but the evidence for the decrease in P. vivax transmission was less clear.
Conclusions: Serological markers pointed to the effectiveness of ITNs in reducing malaria prevalence on Ambae
Island between 2003 and 2007. The recombinant gSG6 antigen originally developed to indicate exposure to the
Afrotropical vector An. gambiae may be used in the Pacific to complement the traditional measure of
entomological inoculation rate (EIR).
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Background
In recent years, analyses of antibody responses to one or
more malaria-specific antigens have been widely used to
assess transmission intensity [1–3], temporal and spatial
reductions in transmission [2, 4], as well as to confirm
elimination [5, 6]. In areas of low transmission, long-
lasting antibody responses may be easier to detect than
parasite prevalence in human populations or infected
mosquitoes [2], making serological measures useful ad-
junct metrics to measure malaria transmission. Recently,
serological evidence of exposure to malaria has demon-
strated successful interventions in some low-
transmission settings [7–9].
Located at the margin of malaria transmission, Vanuatu
is an archipelago of more than 80 islands in the South Pa-
cific. Malaria is endemic on most of the nation’s 68 inhab-
ited islands [10]. The majority of infections are due to
Plasmodium falciparum and Plasmodium vivax, with
some rare cases of Plasmodium malariae [10, 11]. There
are two seasons in Vanuatu: the dry and cool season from
May to October, and the wet and hot season from Novem-
ber to April. Hence malaria incidence in Vanuatu shows
seasonal fluctuations, which are more pronounced for P.
falciparum than P. vivax [10, 12]. The only known malaria
vector is Anopheles farauti (s.s.), a member of the Anoph-
eles punctulatus complex [13].
Several large-scale control programmes have been im-
plemented in Vanuatu over the past decades. In 1988,
insecticide-treated nets (ITNs) were introduced; by 1992
ITN coverage had reached 27% of Vanuatu’s population
[10]. The sharp decline in malaria incidence during the
1990s was explained by the equitable ITN distribution
that targeted the most vulnerable populations i.e. chil-
dren under five years, their mothers, and pregnant
women [12]. An integrated malaria elimination
programme was initiated on the southern-most island of
Aneityum in 1991 [14]. By the mid-1990s, with a high
degree of commitment from the local communities, mal-
aria had been eliminated from Aneityum [14, 15]. An
acute increase in malaria incidence was observed after
shortages in funding for malaria control in the early
2000s, followed by a decline in incidence after the re-
sumption of distribution of subsidised ITNs. Since 2009,
significant external support has enabled the expansion of
intervention measures including the distribution of free
long-lasting insecticide treated-bed nets (LLINs) to cover
more than 80% of the population, focal indoor residual
spraying (IRS), the introduction of free rapid diagnostic
test (RDT) and free artemisinin-based combination ther-
apy (ACT) to all health facilities, and enhanced surveil-
lance and rapid response to identified cases. Further
decrease in malaria incidence since 2009 has put
Vanuatu on course to achieve malaria elimination in the
near future [16].
This study reports on the parasitological and sero-
epidemiological results from samples collected on
Ambae Island in 2003 and 2007. In addition to re-
sponses to antigens from P. falciparum and P. vivax, ex-
posure to vector mosquito bites was also evaluated, with
the aim to determine the effect of vector control on
parasite prevalence. The three parasite antigens used in
this study vary in immunogenicity. The Plasmodium
crude schizont extract (SE) is multi-antigenic and has
greater sensitivity to detect low residual transmission
and changes in transmission intensity [7, 17]. The
blood-stage antigen merozoite surface protein-119 (MSP-
119) exhibits moderate immunogenicity and has been
useful for estimating malaria transmission in populations
across a gradient of transmission intensity [1]. The
blood-stage apical membrane antigen-1 (AMA-1) is
highly immunogenic and induces long-lived immune re-
sponses. In moderate transmission settings, seroconver-
sion occurs more rapidly for AMA-1 than MSP-119 [2,
7]. The An. gambiae salivary gland antigen (gSG6)
showed strong immunogenicity among African popula-
tions in previous studies [18, 19]. The short-lived anti-
bodies against gSG6 appear to correlate with changes in
Anopheles abundance [20], which is useful for evaluating
vector control strategies [21].
Methods
Study sites and sample collection
Ambae Island (398 km2) is in Penama Province (Fig. 1)
and has a population of 10,407 (Vanuatu National Cen-
sus, 2009). Transmission of P. falciparum, P. vivax and
P. malariae is ongoing, and the transmission intensity is
characterised as meso-endemic [10, 22]. Samples were
collected during cross-sectional malariometric surveys
conducted in south Ambae in June 2003 (n = 231) and
June 2007 (n = 282). Futuna Island (11 km2) is in Tafea
Province (Fig. 1) and has a population of 535 (Vanuatu
National Census, 2009). In contrast to Ambae, Futuna
lies beyond the Buxton line, which defines the southeast-
ern limit of anopheline mosquito breeding, thus has al-
ways been free of malaria [10, 14, 17, 23, 24]. Samples
were collected in July 2011 (n = 392) and were included
in the analyses of parasite prevalence and vector expos-
ure only.
Informed consent was obtained from all participants.
The consent procedure was witnessed by a third party
(e.g. teacher, village chief ), who also recorded the name
of each participant as he/she enrolled in the survey.
Gender and age were recorded for each participant. Ax-
illary body temperature was determined using a digital
thermometer (Terumo, New Jersey, US). Fever was de-
fined as a temperature exceeding 37.5 °C. Spleen size
was assessed in children aged 12 years and younger ac-
cording to Hackett’s method by one investigator only
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(AK). Blood samples were obtained for microscopic
examination of malaria infections. Two spots of blood
(70 μl each) were collected on Whatman 31ET Chr filter
paper (Whatman, Maidstone, UK). The blood spots were
air-dried and stored in plastic bags at ambient
temperature in the field and later at -20 °C in our la-
boratories until processing. This study was approved by
the Ministry of Health in Vanuatu and by the
Committee on the Ethics of Human Research of Karo-
linska Institutet in Sweden.
Parasite prevalence by microscopy
Thin and thick blood smears were stained with 3%
Giemsa solution for 30 min and examined under oil
immersion (1,000× magnification) by experienced mi-
croscopists. Blood smears were defined as negative if no
Fig. 1 Locations of Ambae Island and Futuna Island in Vanuatu. The names of the six provinces in Vanuatu are underlined, and approximate
provincial boundaries are indicated by dashed lines. Inset shows the location of Vanuatu. The map was created with ArcGIS software, version
10.4, http://www.esri.com/
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parasites were found after examining 100 high power
microscopy fields. For all positive samples, malaria spe-
cies were identified, and the presence of P. falciparum
gametocytes was recorded.
Assay of anti-malarial antibody responses
A blood spot (3 mm in diameter) was punched from
each sample and antibodies were eluted in reconstitution
buffer in 0.5 ml deep well plates (Corning Costar, PA,
USA) as described previously [25]. The reconstituted
blood spot solution, equivalent to a 1:200 dilution of
serum, was stored at 4 °C until use.
All sera from Ambae were tested for IgG antibodies
by indirect quantitative enzyme-linked immunosorb-
ent assay (ELISA) to crude schizont extract (SE), the
19 kDa fragment of recombinant merozoite surface
antigen-1 (MSP-119), and recombinant apical mem-
brane antigen-1 (AMA-1) for P. falciparum (PfSE,
PfMSP-119 [Wellcome strain], and PfAMA-1 [3D7
strain]) and P. vivax (PvSE, PvMSP-119 [Belem strain],
and PvAMA-1 [Sal-1 strain]) as described previously
[25]. Crude SE of P. falciparum and P. vivax antigens
were prepared as previously described [26, 27].
Briefly, NUNC-Immuno plates (Sigma-Aldrich, St.
Louis, USA) were coated with 50 μl of coating buffer
containing SE, AMA-1 and MSP-119 at 0.5 μg/ml.
The plates were washed in PBS with 0.05% Tween 20
(PBS/T) and blocked using 1% (w/v) skimmed milk
(Sigma-Aldrich) in PBS/T for three hours. After wash-
ing, 50 μl of reconstituted serum were added in du-
plicate. The final antigen dilutions were 1:1000 for SE
and MSP-119, and 1:2000 for AMA-1. In addition,
four blank wells and a five-fold dilution series of an
African hyper-immune serum pool (n = 12) were
added per plate. The plates were washed and 50 μl of
horseradish peroxidase (HRP)-conjugated rabbit anti-
human IgG antibody (DAKO, Glostrup, Denmark)
was added at a dilution of 1:15,000 in PBS/T and in-
cubated for 3 h. After further series of washes, anti-
body responses were detected after development with
100 μl of the substrate solution 3, 3', 5, 5'-Tetra-
methylbenzidine (TMB) (tebu-bio laboratories, Le
Perrey-en-Yvelines, France) for 15 min. The reaction
was stopped with 50 μl of 2 M H2SO4. The optical
density was read using Multiskan Go ELISA reader
(Thermo Fisher Scientific, Waltham MA, USA) at
450 nm.
All samples from Ambae and Futuna were tested for
exposure to bites of An. farauti (s.s.) using the recom-
binant An. gambiae salivary gland gSG6 antigen [19].
ELISA was performed as described above for the parasite
antigens, with the exception that NUNC-Immuno plates
(Sigma-Aldrich) were coated with the recombinant
antigen at 5 μg/ml in 50 μl of coating buffer (final anti-
gen dilution of 1:100).
Statistical methods
Data were double-entered and imported in STATA/SE
version 13.1 (StataCorp, TX, USA). Optical density (OD)
values were averaged and normalised against values from
blank wells to adjust for background reactivity as previ-
ously described [25]. Seropositivity was determined by
fitting a mixture model to normalised OD values assum-
ing two Gaussian distributions, one for seronegative in-
dividuals and another for seropositive individuals [3].
The mean OD plus three standard deviations associated
with the seronegative group was used as the cut-off
value for seropositivity. A separate cut-off was generated
for each antigen. Differences in proportions were tested
using the Chi-squared test or the Fisher’s exact test.
Antibody levels among populations were compared
using the Mann-Whitney U test or the Kruskal-Wallis
test with Dunn’s multiple comparison post-hoc tests.
Pairwise correlations between ODs of different antibody
responses were determined using the Spearman’s rank
correlation. Seroprevalence was stratified into yearly age
groups and then analysed using a reverse catalytic mod-
elling approach under a binomial sampling assumption,
as described elsewhere [1, 9, 28]. This provides an esti-
mate of the mean annual rates of conversion to seroposi-
tive (seroconversion rate, SCR [λ]) and reversion to
seronegative (seroreversion rate, SRR [ρ]), averaged over
the age of the population. Infants under 1 year of age
were excluded to remove any influence of maternally de-
rived antibodies [1]. Logistic regression was used to
identify factors associated with seropositivity to any
parasite-specific antigens and gSG6. In the regression
analysis, seropositivity to Plasmodium was defined as be-
ing positive for either or both species-specific antigens
(MSP-119 and/or AMA-1). Survey year, gender, age
group, fever, and infection status were considered as ex-
planatory variables in the univariate analyses. All vari-
ables with a P-value of ≤ 0.05 from the likelihood ratio
test in the univariate analyses were included in the
multivariate logistic regression model. The variables in-
cluded in the final (adjusted) model was survey year and
age group.
Results
Characteristics of the study population and parasite
prevalence
In total, 231 and 282 people were sampled from Ambae
in 2003 and 2007, respectively; 392 people were re-
cruited from Futuna in 2011. Most the sampled popula-
tions were 20 years old and younger. On Ambae, the
gender ratio and age distribution of the samples did not
differ between 2003 and 2007 (Table 1). The prevalence
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of fever, enlarged spleen in children, as well as Plas-
modium infections were significantly lower in 2007
than in 2003 (Table 1; Chi-square test or Fisher’s
exact test: all P < 0.01). In both sampled years, most
Plasmodium infections were found in children 10 years
and younger (Fig. 3a). Plasmodium malariae was
found in only two individuals in 2003, both of whom
were co-infected with P. falciparum. The decrease in
prevalence was more apparent for P. falciparum
(-9.9%) than P. vivax (-5.1%), resulting in a shift in
species composition from the predominance of P. fal-
ciparum in 2003 to the co-dominance of P. falcip-
arum and P. vivax in 2007. The prevalence of P.
falciparum gametocytes also decreased significantly
(Fisher’s exact test: P < 0.001) between the sampled
years (Table 1).
As expected, no malaria infection was detected on Fu-
tuna. The prevalence of enlarged spleen in children on
Futuna was significantly lower (Fisher’s exact test: both
P < 0.001) than that from Ambae in both 2003 and 2007.
The prevalence of fever on Futuna was similar to that
on Ambae in 2003 (Table 1). These fever cases were
likely caused by other infections, but they were not ex-
plicitly investigated during our survey.
Breadth and correlation of different antibody responses
Antibody levels as measured in optical densities are
shown in Fig. 2. The median anti-gSG6 antibody level
Table 1 Sample characteristics, clinical and parasitological results for all surveyed islands by year [%, (n)]
Ambae Futuna
Characteristic Category 2003 2007 P-valuea 2011 P-valueb
(n = 231) (n = 282) (n = 392)
Gender Female 52.8 (122) 53.9 (152) 0.859 51.0 (200) 0.752
Median age (IQRc) 16 (7–27) 12 (6–26) 0.653 14 (8–25) 0.877
Age group in years 0–5 17.7 (41) 23.0 (62) 0.268 15.8 (62) 0.120
6–10 22.5 (52) 20.2 (57) 0.588 18.9 (74) 0.552
11–20 24.2 (56) 19.5 (55) 0.198 35.7 (140) < 0.001
> 20 35.5 (82) 38.3 (108) 0.522 29.6 (116) 0.051
Fever (> 37.5 °C) 8.2 (19) 0.0 (0) < 0.001 8.2 (32) < 0.001
Enlarged spleen (< 12 years old) 69.8 (74/106) 28.8 (23/80) < 0.001 2.9 (2/70) < 0.001
Parasite prevalence 19.0 (44) 3.2 (9) < 0.001 0 (0) < 0.001
Species-specific prevalence P. falciparum 11.7 (27) 1.8 (5) < 0.001 0 (0) < 0.001
P. vivax 6.5 (15) 1.4 (4) 0.004 0 (0) < 0.001
P. malariae 0.9 (2) 0.0 (0) 0.204 0 (0) 0.054
Gametocyte prevalenced P. falciparum 7.8 (18) 0.7 (2) < 0.001 0 (0) < 0.001
a Proportion or median level of each category between two surveys on Ambae Island (2003 and 2007)
b Proportion or median level of each category among all three surveys (Ambae Island in 2003 and 2007 and Futuna Island in 2011)
c IQR: interquartile range (25–75th percentile)
d No P. vivax and P. malariae gametocytes were detected by microscopy
Fig. 2 Species-specific antibody responses to An. gambiae salivary gland gSG6 antigen (a), P. falciparum antigens (b), and P. vivax antigens (c).
The interquartile range (IQR, 25–75th percentile) is represented in a box plot with the median OD value shown as a line within the box.*P < 0.05;
**P < 0.01; ***P < 0.001
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showed a significant (Mann-Whitney U-test: Z = 6.57, P
< 0.001) decrease on Ambae between 2003 and 2007. No
significant difference in gSG6 antibody levels was ob-
served between Ambae in 2007 and Futuna, where
Anopheles vectors are absent. Similar to the decrease in
anti-gSG6 antibody levels, median antibody levels to all
P. falciparum and P. vivax antigens also decreased sig-
nificantly (Kruskal-Wallis H-test: all P < 0.01) on Ambae
between the survey years. Significant (Kruskal-Wallis H-
test: all P < 0.05) differences in median antibody levels
were observed among parasite-specific antigens on
Ambae in 2007. For P. falciparum, the anti-SE antibody
level was significantly (Mann-Whitney U-test: both P <
0.01) higher than the anti-MSP-119 and anti-AMA-1
levels. For P. vivax, the anti-AMA-1 antibody level was
significantly (Mann-Whitney U-test: both P < 0.05)
higher than the anti-SE and anti-MSP119 levels.
Antibody responses were significantly correlated
among all antigens, although the strength of correlation
varied (Table 2). In general, the correlations were stron-
ger between antibody responses to antigens of the same
species (e.g. PfSE vs PfMSP-119) than between those of
orthologous antigens (e.g. PfMSP-119 vs PvMSP-119).
Weaker correlations were observed between antibody re-
sponses to gSG6 and the parasite antigens (Spearman’s r
= 0.11–0.20, P < 0.01).
Seroprevalence in the populations
Figure 3 shows the overall seroprevalence to parasite an-
tigens on Ambae. Among all parasite antigens, sero-
prevalence to crude SE was highest for both P.
falciparum and P. vivax. Similar to parasite rate and
other malaria indices, seroprevalence was significantly
higher (Chi-square test or Fisher’s exact test: all P <
0.001) in 2003 than in 2007 for all parasite antigens ex-
cept PvAMA-1. No significant difference was observed
in seroprevalence between males and females for any of
the antigens tested (Chi-square test or Fisher’s exact test:
all P > 0.05). For all parasite antigens, the proportion of
seropositive individuals significantly increased with age
(Chi-square test: all P < 0.001). Seroprevalence to gSG6
is shown in Fig. 3b. As expected from an island without
anopheline mosquitoes, all samples from Futuna were
seronegative. On Ambae, a significant (Fisher’s exact
test: P < 0.001) decrease in seroprevalence to gSG6 was
observed, from 39% in 2003 to 0.7% in 2007. Neverthe-
less, gSG6 seroprevalence in 2003 was similar among
age groups.
Changes in SCR
The relationship between seroprevalence and age on
Ambae was further examined using reversible catalytic
conversion models. Seroconversion curves for parasite
antigens are shown in Fig. 4. As was observed for the
overall seroprevalence, the SCRs for all P. falciparum
antigens significantly decreased between 2003 and 2007
on Ambae, as evidenced by the non-overlapping confi-
dence intervals. The resulting SCRs suggest at least a
three-fold decrease in P. falciparum transmission on
Ambae. For P. vivax, significant decreases in SCRs were
observed for SE and MSP-119, but not for AMA-1 be-
tween 2003 and 2007. The decreases in SCRs were
smaller in magnitude for P. vivax antigens than their
counterparts for P. falciparum.
Variables associated with seropositivity
We performed univariate and multivariate logistic re-
gression analyses to identify factors associated with sero-
positivity to any P. falciparum and P. vivax specific
antigens, as well as Anopheles gSG6 on Ambae Island
(Table 3). In the adjusted model, the survey year 2007
was significantly associated with lower seropositivity to
all antigens tested. Significant associations were found
between age and seropositivity to both P. falciparum
and P. vivax antigens. For P. falciparum antigens, the
likelihood of seropositivity increased significantly with
age, whereas for P. vivax, the increase in seropositivity
was significant among adults aged > 20 only. No associ-
ation was found between age and seropositivity to the
vector salivary gSG6 antigen.
Table 2 Pairwise correlation (Spearman’s rank correlation coefficient) between IgG responses to parasite and mosquito antigens. All
correlations were significant (P < 0.01)
SE MSP-119 AMA-1 gSG6
Antigen Species Pf Pv Pf Pv Pf Pv Ag
SE Pf
Pv 0.5776
MSP-119 Pf 0.7635 0.4741
Pv 0.4171 0.6595 0.4325
AMA-1 Pf 0.5982 0.4396 0.6074 0.3595
Pv 0.4367 0.5821 0.3632 0.465 0.3128
gSG6 Ag 0.1750 0.1934 0.1168 0.132 0.1937 0.1139
Abbreviations: Pf , P. falciparum; Pv, P. vivax; Ag, An. gambiae
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Discussion
Following a gap in funding from external donors that
negatively impacted ITN coverage, Vanuatu experienced
a resurgence of malaria incidence in the first half of the
2000s. In 2003, Vanuatu secured financial support from
the Global Fund to resume distribution of subsidised
ITNs. Subsequent decreases in slide positivity rate and
proportion of cases caused by P. falciparum at the na-
tional level were observed after 2006 (16). In this study,
we examined the parasite prevalence and IgG antibody
responses to antigens from the two major Plasmodium
species as well as Anopheles vector on Ambae Island in
2003 and 2007, marking the peak of the resurgence and
its subsidence, respectively. A significant decrease in
parasite prevalence was accompanied by significant de-
creases in seropositivity to most parasite antigens and
the vector salivary antigen, suggesting that reinforced
vector control played an important role in the reduction
of malaria transmission on Ambae.
The shift in species predominance on Ambae between
2003 and 2007 was consistent with the nation-wide de-
crease in the proportion of P. falciparum cases. As ITN
was the main intervention tool used during the study
period, the shift to P. falciparum-P. vivax co-dominance
in 2007 suggests that ITNs were more protective against
P. falciparum-infected mosquitoes. Previously in Papua
New Guinea, differential ITN protection was partially ex-
plained by differences in biting behaviour of An. punctula-
tus mosquitoes infected with different parasite species,
with a higher proportion of P. vivax-infected mosquitoes
biting humans earlier in the evening (25). Furthermore,
ITNs provide no protection against P. vivax relapse from
hypnozoites, which might explain the increase in the pro-
portion of P. vivax cases in our study site as well as others,
where overall malaria incidences have declined as a result
of effective interventions [6, 29, 30].
The greater decrease in P. falciparum prevalence be-
tween 2003 and 2007 was reflected in the more pro-
nounced reduction in seroprevalence to P. falciparum
antigens, especially AMA-1 (Fig. 3). The net decrease in
seroprevalence to PfAMA-1 (-0.212) was more than nine
times higher than the net decrease in seroprevalence to
PvAMA-1 (-0.023). In contrast, the net decrease in sero-
prevalence to crude SE was similar between P. falcip-
arum (-0.244) and P. vivax (-0.239). It should be noted
that crude SE contains multiple proteins, of which some
are similar between parasite species [7]. Antibodies to
crude SE might therefore not be species-specific, and
cross-reactive antibodies might have masked the differ-
ence in exposure between P. falciparum and P. vivax.
Fig. 3 Age-specific parasite prevalence by microscopy and antibody response in Ambae Island and Futuna Island. Graphs are divided by year of
sampling and in four age groups for: (a) Microscopy, (b) An. gambiae salivary gland gSG6 antigen, (c) P. falciparum antigens, and (d) P. vivax
antigens. Serological analyses for P. falciparum and P. vivax antigens were performed for samples from Ambae Island only. Numbers above bars
show the numbers of positive individuals
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Seroprevalence reflects cumulative malaria exposure
and can be used to estimate transmission intensity in a
population. Modelling changes between seroprevalence
and age (i.e. SCR) can help evaluate specific interventions
in an area. In practice, SCR is calculated by fitting a re-
versible catalytic model to the age-specific malaria sero-
prevalence data, taking into account malaria exposure
over time [28]. SCR describes the frequency per unit time
(e.g. year) at which seronegative individuals becomes sero-
positive, and is related to the underlying force of infection
[1]. Since serological data integrate exposure over time, they
can reveal changes in transmission (e.g. recent outbreak) [3,
7]. In this study, statistical analyses of the seroprevalence
profiles suggested that serological response generally in-
creased with age and malaria transmission intensity de-
creased dramatically on Ambae between 2003 and 2007.
SCRs estimated from the age-adjusted seroprevalence
curves for P. falciparum antigens were higher than the ones
for P. vivax antigens, reflecting the more intense
transmission and the predominance of the former species
on Ambae, especially in 2003 (Fig. 3). Changes in P. falcip-
arum transmission were readily detected and the estimated
decreases in transmission intensity were consistent across
the three antigens used: 74.0% for PfSE (SCR from 0.365 to
0.095), 70.2% for PfMSP-119 (0.114 to 0.034), and 66.9% for
PfAMA-1 (0.127 to 0.042). For P. vivax, the decreases in
transmission were more variable: 69.8% for PvSE (0.043 to
0.013), 60.0% for PvMSP-119 (0.020 to 0.008), and 13.3% for
PvAMA-1 (0.015 to 0.013). It is unclear why the estimates
from PvMSP-119 and PvAMA-1 were drastically different.
The difference in SRR, subclass dependent half-life, inher-
ent immunogenicity, and polymorphism or diversity be-
tween the two antigens may explain some of the variation
in estimates [3]. Similar observations have also been re-
ported previously [7, 31–33].
On Aneityum Island, SCRs decreased by 85.0% (0.04
to 0.006) for PfSE and 93.3% (0.03 to 0.002) for PvSE
seven years after the implementation of an integrated
Fig. 4 Trends in age-seroprevalence curves and seroconversion rates (SCRs) for all P. falciparum and P. vivax antigens on Ambae Island. SCR or lambda
(λ) was estimated by fitting reversible catalytic conversion models to data from all available age groups. Resulting SCRs and 95% confidence intervals
for both years (2003 and 2007) are presented on the graph. The P. falciparum fixed seroreversion rates (SRRs) for PfSE, PfMSP-119 and, PfAMA-1 were
0.001 year-1 (0.000–0.388), 0.072 year-1 (0.042–0.125) and, 0.196 year-1 (0.096–0.402), respectively. The P. vivax fixed SRRs for PvSE, PvMSP-119 and,
PfAMA-1 were 0.016 year-1 (0.004–0.063), 0.015 year-1 (0.003–0.078) and, 0.042 year-1 (0.014–0.131), respectively
Idris et al. Parasites & Vectors  (2017) 10:204 Page 8 of 12
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malaria elimination programme in 1991 [17]. The ob-
served reductions on Ambae (74.0% for PfSE and 69.8%
for PvSE) were less impressive than those on Aneityum,
although the study duration on Ambae was shorter (four
years). On Aneityum, seroprevalence curves revealed a
distinct change in the force of infection corresponding to
the abrupt cessation of transmission (19). In contrast, the
decrease in transmission on Ambae appeared more grad-
ual (Fig. 3). The absence of a step change in transmission
may also be explained by the small size of our samples
[34, 35]. Additional follow-up studies with samples from
more recent years will be needed to confirm the long-
term effect of malaria control interventions on Ambae.
Antibody response to salivary antigen gSG6 was previ-
ously shown to be a reliable indicator of human expos-
ure to Afrotropical malaria vectors [19, 20, 36–38]. The
SG6 protein first identified in An. gambiae [39], was fur-
ther reported to be highly conserved among a few
Anopheles species [40] and under purifying selection in
an An. gambiae population from Burkina Faso [41].
Comparison of SG6 protein sequences among 16 Anoph-
eles species [42] showed that the An. gambiae gSG6
shares high degrees of identity with orthologues from
the main African (An. arabiensis, 98%; An. funestus,
80%), Asian (An. stephensi and An. maculatus, 79%; An.
culicifacies, 72%; An. sinensis, 61%; An. dirus, 54%) and
European (An. atroparvus, 66%) malaria vectors,
whereas a more limited identity (52%) was found with
An. farauti (B. Arcà et al. unpublished data). Notably,
SG6 is absent in An. albimanus and An. darlingi, mem-
bers of the subgenus Nyssorhynchus and important mal-
aria vectors in Central and South America. The current
study is the first to describe the use of recombinant
gSG6 antigen to evaluate exposure to Anopheles bites in
the Pacific, where all major malaria vectors belong to
the An. punctulatus group [13]. Anopheles farauti (s.s.),
the only malaria vector in Vanuatu, is absent on Futuna
Island (10, 13). Accordingly, all participants from Futuna
in this study were seronegative to gSG6 (Fig. 3b). On
Ambae, exposure to Anopheles mosquito bites was
greatly reduced, evidenced by the decrease in seropreva-
lence to gSG6 from 39% in 2003 to 0.7% in 2007. This
reduction in vector exposure suggested the positive im-
pact of ITN distribution after 2003 on vector population
density and/or changes in vector behaviour (e.g. prefer-
ence and aggressiveness towards humans). Nevertheless,
a recent survey showed lower ITN use on Ambae (68%)
than on Aneityum (73%), where elimination-specific ef-
fort has successfully halted malaria transmission [22].
Anti-gSG6 antibody response on Ambae closely
followed patterns of decreases in malaria prevalence and
community-level antibody responses to all parasite anti-
gens except PvAMA-1. This finding is in agreement with
previous reports of malaria incidence and Anopheles-
and malaria-specific antibody responses in Africa [18,
38, 43]. Previous studies showed the utility of the gSG6
antigen in evaluating the short-term (< one year) efficacy
of ITN use [44, 45]. In this study, we demonstrated that
gSG6 might also be useful for long-term monitoring. As
Vanuatu and neighbouring Solomon Islands embark on
malaria elimination (17), serological tools to measure ex-
posure to vectors may become more important as the
standard EIR becomes more difficult to determine accur-
ately at low transmission settings (41).
A number of caveats should be considered in this study.
The most obvious one concerns the relatively small number
of individuals sampled in each year. As small sample sizes
might be sufficient to detect a significant reduction in SCR
[35], but invariantly lead to poor estimation precision of
current SCR and limit the likelihood of identifying signifi-
cant changes point in malaria transmission over time for
the reverse catalytic model [34, 35]. Samples were also col-
lected using a convenience sampling method. Although this
approach is valid in obtaining an estimate of antimalarial
antibody prevalence [3], it can result in an overestimation
of malaria incidence in the area. While the recombinant
An. gambiae gSG6 antigen could be used to measure ex-
posure to An. farauti bites in Vanuatu, the limited conser-
vation between the SG6 protein from these two species
(52% identity, 70% similarity) likely result in lower detection
sensitivity. Serological analyses using more sensitive bio-
marker such as cE5 may provide a more accurate measure
of exposure to vectors in a population (42). Parasite preva-
lence in the current study was determined solely by micros-
copy which likely underestimated the true prevalence.
Molecular screening by PCR consistently detects at least
twice as many infections as microscopy [46]. Recent studies
have confirmed that in malaria-endemic areas sub-
microscopic (microscopy negative but PCR positive) P. fal-
ciparum and P. vivax infections are common [47, 48]. The
prevalence of these sub-microscopic infections and their
contribution to malaria burden are age-dependent [49]. In
areas of very low transmission sub-microscopic carriers are
estimated to be the source of 20–50% of all human-to-
mosquito transmissions [46]. Considering that malaria
transmission has decreased further in Vanuatu, assessing
sub-microscopic parasite carriage will be critical in moni-
toring malaria elimination measures.
Conclusions
This study showed the decreases in malaria prevalence
and antibody responses to crude SE, MSP-119, and
AMA-1 from P. falciparum and P. vivax on Ambae Is-
land, Vanuatu between 2003 and 2007. These decreases
were matched by a reduction in seroprevalence to the
Anopheles-specific salivary gSG6 antigen, suggesting that
ITNs were effective in suppressing malaria transmission.
This study also demonstrated the utility of recombinant
Idris et al. Parasites & Vectors  (2017) 10:204 Page 10 of 12
gSG6, originally developed to measure exposure to Afro-
tropical vectors, in the Pacific where the An. punctulatus
group is endemic. Larger follow-up surveys are required
to examine more subtle changes in transmission.
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